The Government of Delhi has issued an urgent public alert warning consumers, chemists, and distributors against the sale and use of the cough syrup COLDRIF Syrup, after the formulation was declared “Not of Standard Quality” and unsafe for human use by the Drugs Testing Laboratory, Food & Drugs Administration, Madhya Pradesh.
⚠️ Drug Details
- Name: COLDRIF Syrup
(Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate Syrup) - Batch Number: SR13
- Manufacturing Date: May 2025
- Expiry Date: April 2027
- Manufacturer: Sresan Pharmaceutical Manufacturer,
No. 787, Bangalore Highways, Sunguvachatram (Mathura),
Kancheepuram District, Tamil Nadu – 612106
💊 Reason for Alert
According to the laboratory’s Test Report No. 68N dated 04.10.2025, the sample of COLDRIF Syrup was found to contain Diethylene Glycol (DEG) at 46.28% w/v, a toxic and adulterated substance that renders the product injurious to health.
Diethylene Glycol is a highly poisonous compound that can cause acute kidney failure, liver damage, central nervous system depression, and even death when ingested.
🚫 Directive to Stakeholders
In light of these findings, the Government of Delhi has directed:
- All wholesalers, distributors, retailers, and pharmacists to immediately stop the purchase, sale, and distribution of COLDRIF Syrup.
- Healthcare professionals to avoid prescribing or dispensing the said product.
- Public health authorities to ensure the withdrawal of existing stocks from the market.
The alert emphasises strict compliance from all stakeholders to prevent any further circulation of the unsafe drug.
👥 Advisory for the Public
Citizens are strongly advised not to consume COLDRIF Syrup of the above-mentioned batch or any unverified stock currently in circulation.
Those who may have already used the syrup should:
- Stop its use immediately.
- Consult a registered medical practitioner if they experience any unusual symptoms.
- Report suspected adverse reactions to the nearest health authority or the Drugs Control Department, Delhi.
📢 Public Health Concern
The alert underscores the critical need for vigilance among both consumers and medical retailers to ensure that substandard or adulterated drugs do not enter the supply chain.
The presence of Diethylene Glycol in medicinal formulations has previously been linked to multiple fatalities worldwide, prompting strict regulatory actions across India.
✅ Conclusion
The Delhi Government’s Office of the Drugs Controller has issued this order in the interest of public health and safety, urging all stakeholders to ensure immediate compliance and wide dissemination of this alert.
Consumers are reminded to purchase medicines only from licensed pharmacies and to check manufacturer details and batch numbers carefully before use.